Skip to the beginning of the images gallery

Adalimumab (anti-TNF-alpha), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to TNFSF2/TNFa, >95% (SDS-PAGE&SEC), high purity, Human IgG1, INHIBITOR of TNF-alpha inhibitor

≥95%(SDS-PAGE&SEC)
Lot by Lot

Application:

Animal Model
ELISA
Flow Cytometry
Functional Assay

Features and benefits

Host species: Human
Species reactivity(Reacts with): Cynomolgus monkey,Human,Mouse,Rhesus monkey
Isotype: Human IgG1
Conjugation: Unconjugated

Item Number

A412002

Grouped product items
SKU	Size	Availability	Price
A412002-100μg	100μg	In stock	$39.90
A412002-1mg	1mg	In stock	$159.90
A412002-5mg	5mg	In stock	$664.90
A412002-10mg	10mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$1,196.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level < 0.01EU/μg ; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

View related series

Click to view target information: ELANE Click to view target information: PRTN3 Click to view target information: TNF

Accession#:P01375 Anti-infection Apoptosis Bacterial Gene ID:7124 TNF TNF Receptor TNF-alpha

Basic Description

Product Name	Adalimumab (anti-TNF-alpha), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to TNFSF2/TNFa, >95% (SDS-PAGE&SEC), high purity, Human IgG1
Synonyms	dl-N-Acetylhomocysteinethiolactone \| ONO5046;LY544349;EI546 \| SIVELESTAT [INN] \| SIVELESTAT [MART.] \| 2,2-Dimethyl-propionic acid 4-[2-(carboxymethyl-carbamoyl)-phenylsulfamoyl]-phenyl ester \| P,.ALPHA.,.ALPHA.-TRIMETHYLBENZYL ALCOHOL [FHFI] \| J-005486 \|
Specifications & Purity	ExactAb™, Validated, Carrier Free, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
Host species	Human
Specificity	TNFSF2/TNFa
Application	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
Conjugation	Unconjugated
Grade	Azide Free, Carrier Free, ExactAb™, Recombinant, Validated
Action Type	INHIBITOR
Mechanism of action	INHIBITOR of TNF-alpha inhibitor
Product Description	Adalimumab (anti-TNF-α) is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α). Purity>95% (SDS-PAGE&SEC) Endotoxin Level< 0.01EU/μg

Product Properties

Antibody Type	Primary antibody
Clonality	Recombinant
Isotype	Human IgG1
Light Chain Type	kappa
SDS-PAGE	145.5 kDa
Purification Method	Protein A purified
Purity	>95% (SDS-PAGE&SEC)
Source	CHO supernatant
Form	Liquid
Concentration	Lot by Lot
Storage Temp	Store at -80°C,Avoid repeated freezing and thawing
Shipped In	Ice chest + Ice pads
Stability And Storage	Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS	331731-18-1

Images

Adalimumab (anti-TNF-alpha) (A412002) - ELISA
Immobilized Recombinant Human TNF-α Protein (rp156007) at 1.0 μg/mL can bind Golimumab (anti-TNFa) (Ab175552) with the EC₅₀ of 5.78 ng/mL.

Adalimumab (anti-TNF-alpha) (A412002) - SEC
The purity of Adalimumab (anti-TNF-alpha) (A412002) is more than 95% verified by HPLC.

Associated Targets(Human)

ELANE Tclin Neutrophil elastase (12 Activities)

Discover Target: ELANE

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PRTN3 Tchem Myeloblastin (1 Activities)

Discover Target: PRTN3

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

TNF Tclin Tumor necrosis factor (0 Activities)

Discover Target: TNF

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Wikipedia

Adalimumab

IMGT/mAb-DB

165

PEP

adalimumab

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot Number	Certificate Type	Date	Item
ZJ24F0303693	Certificate of Analysis	Mar 26, 2024	A412002
ZJ24F0303692	Certificate of Analysis	Mar 26, 2024	A412002
ZJ24F0303691	Certificate of Analysis	Mar 26, 2024	A412002

References

1. Kempeni J. (1999) Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7.. Ann Rheum Dis, 58 Suppl 1 (13): (I70-2). [PMID:10577977] [10.1021/op500134e]
2. Wollheim FA. (2002) TNF inhibition as therapy for rheumatoid arthritis.. Expert Opin Investig Drugs, 11 (7): (947-53). [PMID:12084005] [10.1021/op500134e]
3. Rau R. (2002) Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials.. Ann Rheum Dis, 61 Suppl 2 (13): (ii70-3). [PMID:12379628] [10.1021/op500134e]
4. Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D et al.. (2016) Adalimumab in Patients with Active Noninfectious Uveitis.. N Engl J Med, 375 (10): (932-43). [PMID:27602665] [10.1021/op500134e]
5. Kawalec P, Mikrut A, Wiśniewska N, Pilc A. (2013) Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis.. Arch Med Sci, 9 (5): (765-779). [PMID:24273556] [10.1021/op500134e]
6. Puri A, Niewiarowski A, Arai Y, Nomura H, Baird M, Dalrymple I, Warrington S, Boyce M. (2017) Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects.. Br J Clin Pharmacol, 83 (7): (1405-1415). [PMID:28133772] [10.1021/op500134e]
7. Jani RH, Gupta R, Bhatia G, Rathi G, Ashok Kumar P, Sharma R, Kumar U, Gauri LA, Jadhav P, Bartakke G et al.. (2016) A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.. Int J Rheum Dis, 19 (11): (1157-1168). [PMID:26176644] [10.1021/op500134e]
8. Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B. (2017) Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.. Br J Dermatol, 177 (6): (1562-1574). [PMID:28755394] [10.1021/op500134e]
9. Kronthaler U, Fritsch C, Hainzl O, Seidl A, da Silva A. (2018) Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications.. Expert Opin Biol Ther, 18 (8): (921-930). [PMID:29962245] [10.1021/op500134e]
10. Schreiber S, Yamamoto K, Muniz R, Iwura T. (2020) Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab.. Pharmacol Res Perspect, 8 (3): (e00604). [PMID:32500668] [10.1021/op500134e]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.